Janus Henderson Group PLC Buys 225,105 Shares of Glaukos Corporation (GKOS)
Janus Henderson Group PLC grew its stake in shares of Glaukos Corporation (NYSE:GKOS) by 7.2% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,344,361 shares of the medical instruments supplier’s stock after buying an additional 225,105 shares during the quarter. Janus Henderson Group PLC owned 9.68% of Glaukos worth $110,364,000 at the end of the most recent quarter.
Other large investors also recently made changes to their positions in the company. Ameritas Investment Partners Inc. grew its stake in shares of Glaukos by 93.1% in the second quarter. Ameritas Investment Partners Inc. now owns 2,514 shares of the medical instruments supplier’s stock worth $104,000 after purchasing an additional 1,212 shares during the last quarter. BNP Paribas Arbitrage SA grew its stake in shares of Glaukos by 740.6% in the second quarter. BNP Paribas Arbitrage SA now owns 3,539 shares of the medical instruments supplier’s stock worth $147,000 after purchasing an additional 3,118 shares during the last quarter. Quantbot Technologies LP grew its stake in shares of Glaukos by 291.3% in the third quarter. Quantbot Technologies LP now owns 7,653 shares of the medical instruments supplier’s stock worth $252,000 after purchasing an additional 5,697 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. bought a new stake in shares of Glaukos in the second quarter worth about $262,000. Finally, UBS Asset Management Americas Inc. bought a new stake in shares of Glaukos in the second quarter worth about $274,000. 99.23% of the stock is currently owned by hedge funds and other institutional investors.
Several research firms recently issued reports on GKOS. BidaskClub raised Glaukos from a “hold” rating to a “buy” rating in a research note on Tuesday, September 12th. Cantor Fitzgerald reissued a “buy” rating and issued a $60.00 target price (up from $54.00) on shares of Glaukos in a research note on Thursday, September 14th. BMO Capital Markets restated a “buy” rating and issued a $54.00 price objective on shares of Glaukos in a report on Friday, September 1st. Stephens restated a “buy” rating and issued a $47.00 price objective on shares of Glaukos in a report on Friday, September 15th. Finally, Piper Jaffray Companies restated a “buy” rating and issued a $38.00 price objective on shares of Glaukos in a report on Friday, September 15th. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $46.57.
Shares of Glaukos Corporation (GKOS) traded up $0.83 on Thursday, reaching $26.60. 95,904 shares of the company’s stock traded hands, compared to its average volume of 646,523. Glaukos Corporation has a twelve month low of $23.08 and a twelve month high of $52.49. The stock has a market capitalization of $906.99 and a price-to-earnings ratio of 215.83.
Glaukos (NYSE:GKOS) last released its earnings results on Tuesday, November 7th. The medical instruments supplier reported $0.04 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.02) by $0.06. Glaukos had a negative net margin of 0.64% and a positive return on equity of 3.50%. The firm had revenue of $40.41 million during the quarter, compared to analyst estimates of $38.69 million. During the same period last year, the business earned $0.03 earnings per share. The business’s revenue was up 36.6% on a year-over-year basis. equities research analysts forecast that Glaukos Corporation will post -0.03 EPS for the current year.
In other Glaukos news, CFO Joseph E. Gilliam bought 2,100 shares of the stock in a transaction dated Wednesday, November 22nd. The stock was purchased at an average cost of $23.84 per share, for a total transaction of $50,064.00. Following the completion of the acquisition, the chief financial officer now owns 102,100 shares of the company’s stock, valued at $2,434,064. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 16.40% of the stock is currently owned by company insiders.
Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.
Want to see what other hedge funds are holding GKOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Glaukos Corporation (NYSE:GKOS).
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.